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ABSTRACT
CD166/ALCAM plays an important role in tumor
aggression and progression as well as protecting
cancer cells against apoptosis and autophagy.
However, the mechanism by which pro-cell death
signals control CD166 expression remains unclear.
Here we show that following serum deprivation (SD),
upregulation of CD166 protein is shorter than that
of CD166 mRNA. Molecular analysis revealed
both CD166 and miR-9-1 as two novel NF-iB
target genes in hepatoma cells. In vivo activation
and translocation of the NF-iB P50/P65 hetero-
dimer into the nucleus following the phosphoryl-
ation and accompanied degradation of its inhibitor,
IiBa, contributes to efficient transcription of
both genes following SD. We show that following
serum starvation, delayed up-regulation of miR-9
represses translation of CD166 protein through its
target sites in the 30-UTR of CD166 mRNA. We also
propose that miR-9 promotes cell migration largely
due to inhibition of CD166. Collectively, the study
elucidates a novel negative auto-regulatory loop
in which NF-iB mediates differential regulation of
CD166 after SD.
INTRODUCTION
CD166, also known as activated leukocyte cell adhe-
sion molecule (ALCAM) or MEMD, is a 105-kDa
transmembrane glycoprotein of the immunoglobin super-
family (1) mapped to human chromosome 3q13 (2). Its
expression has been described in subsets of cells involved
in dynamic growth and migration, including developing
neuronal cells, hematopoietic cells (3), endothelial cells
during embryogenesis, lymphoid and myeloid cells, ﬁbro-
blasts, hepatocytes, pancreatic accinar and islet cells and
bone marrow stromal cells (4). CD166 was studied in
malignant melanoma, where it seems to be signiﬁcantly
correlated with cancer progression and distinguishes the
invasive and metastasizing vertical growth phase of
melanoma from its non-invasive, radial growth phase
(5–7). Additionally, CD166 expression was altered in
prostate and breast cancer carcinoma tissue (8,9). In par-
ticular, upregulation of CD166 mRNA and protein levels
were found in prostate cancer compared with adjacent
normal tissue, with the exception of downregulation in
some high-grade tumors (8). Recently, a novel soluble
isoform of CD166 (sCD166), produced via alternative
splicing, was isolated (10). sCD166 demonstrated an
CD166-independent effect in endothelial cell assays as
well as a regulatory effect on CD166 function. CD166–
CD166 interactions are crucial to the survival and primary
site maintenance of cancer cells (11). Additionally, CD166
gene silencing in breast cancer cells decreased the concen-
tration of BCL-2 and increased levels of apoptosis (PARP,
active caspase7) (12) and autophagy (MAP1LC3, Beclin1)
markers (13), therefore, CD166 may also play an import-
ant role in protecting cancer cells against apoptosis and
autophagy.
Given that CD166 modulates many cellular functions, it
can be hypothesized that aberrant CD166 expression may
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CD166 could represent a novel therapeutic target, as the
underlying mechanism of CD166-mediated carcinogenesis
has been progressively elucidated. However, the exact
regulation of CD166 has yet to be well-described, especial-
ly the mechanism by which pro-cell death signals control
CD166 expression.
In the present study, we observed that CD166 mRNA is
greatly upregulated in hepatoma cell lines after serum
deprivation (SD), a well-known condition which inhibits
cell growth and migration and leads to either apoptosis
(14,15) or autophagy (16,17). However, up-regulation
of CD166 protein is not as prolonged as that of mRNA.
The aim of the present study was to deﬁne the mechanism
responsible for the induction of CD166 after SD and
provide a basic model to aid future studies.
MATERIALS AND METHODS
Materials
Human hepatoma cell lines, HepG2, GQY-7701 and
Bel-7402 were maintained in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) with or without fetal bovine
serum (FBS, Gibco, Carlsbad, CA, USA). The following
primary antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA): Brg I (SC-
10768), RNA polymerase II (SC-9001), CD166/ALCAM
(SC-25624); b-actin (SC-130656); NF-kB P65 (SC-372x),
NF-kB P52 (SC-848x), NF-kB P50 (SC-7178x), c-Rel
(SC-71x), Rel B (SC-48366x), TFIIAa (SC-134080)
and IkBa (SC-847). The anti-phospho-IkBa antibody
(2859) was from Cell Signaling Technology (Boston,
MA, USA). NF-kB inhibitor BAY 11-7082, inhibitor of
translation, cycloheximide (CHX) and bacterial lipopoly-
saccharides (LPS, L2880) were purchased from Sigma
(St Louis, MO, USA). Tumor necrosis factor alpha
(TNFa, 210-TA) was purchased from R&D systems
(Minneapolis, MN, USA). All primers and probes are
available in Supplementary Data.
Cell culture
To examine the effects of NF-kB on CD166 and miR-9
expression, cells were pretreated with 100mM BAY
11–7082 for 1h and then stimulated with SD for another
24h. LPS and TNFa were used at concentrations of
100ng ml
 1 and 10ng ml
 1, respectively. Cells were trans-
fected with miR-9 mimics (50–70nM), miR-9 inhibitor
(50–70nM), siRNA (50nM) against P50, P65, Brg I,
Brm or negative control scramble RNA (GenePharma
Co., Ltd, Shanghai China) using Lipofectamine 2000
(Invitrogen Corp, Carlsbad, CA, USA) according to the
manufacturer’s instructions. Certiﬁcation of interference
effects by siRNA is available in Supplementary
Figure S1. Pre-incubation with 10mM CHX was per-
formed for 30min, followed by serum-deprivation
treatment and further incubation for 1 day in the
continued presence of CHX.
50-RLM-RACE
The GeneRacer system (Invitrogen), based on RNA
ligase-mediated and oligo-capping rapid ampliﬁcation of
cDNA, was carried out according to the manufacturer’s
instructions. CD166-speciﬁc primers were used for ampli-
ﬁcation by PCR using the LaTaq GC-Rich PCR system
(Takara, Inc., Dalian, China). The PCR products were
then cloned into pGEM-T vector (Promega, Madison,
WI, USA) and sequenced.
Chromatin accessibility analysis
Accessibility of DNA to digestion with DNase I or restric-
tion enzymes (all from Takara, except Dde I and Mae III
from New England Biolabs, Beverly, MA, USA) analyzed
using chromatin accessibility by real-time PCR (CHART-
PCR) as described previously (18–20). After puriﬁcation,
0.1mg DNA from nuclease-digested or non-digested
control cells was used in semi-quantitative PCR.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation assay (ChIP) assays were
performed according to the manufacturer’s instructions
(Active Motif, Carlsbad, CA, USA). Brieﬂy, 2 10
6 cells
were ﬁxed with 1% formaldehyde, washed with cold
phosphate-buffered saline and lysed in buffer. Nuclei
were sonicated to shear DNA, and the lysates were
pelleted and precleared. The protein–DNA complexes
were incubated with 4mg antibodies overnight and then
incubated with protein A beads followed by elution in
1% SDS/0.1M NaHCO3 and cross-links were reversed
at 65 C. At last, DNA was subjected to semi-quantitative
PCR analysis after recovered.
Reverse transcription PCR
Total RNA was extracted by Trizol reagent (Invitrogen).
Reaction mixture (20ml) containing 1mg total RNA
was reverse transcribed to cDNA using PrimeScript
RT-polymerase (Takara). Quantitative PCR was per-
formed on the cDNA using primers speciﬁc for CD166,
P50, P65, Brg I, Brm, pri-miR-9-1 and pri-miR-9-2.
Speciﬁcally, Stem-loop reverse transcription (RT)–PCR
for mature miR-9 was performed as described previously
21). RNA input was normalized to the level of b-actin,
both for genes and micro RNA (miRNA) analysis (22).
All reactions were carried out using SYBR Green Mix
(Takara), and the PCR conditions for quantitative
RT–PCR were as follows: activation of enzyme at 94 C
for 5min, 40 cycles of denaturation at 94 C for 30s,
annealing at 55 C for 30s and extension at 72 C for
20s. qRT–PCR was carried out using a Mx3000P
real-time PCR System (Stratagene, La Jolla, CA, USA).
The data from qRT–PCR were analyzed by the Ct
method as previously described (20,23).
Construction of plasmids and mutagenesis
PCR was performed using sets of primers speciﬁc for the
CD166 and pri-miR-9-1 promoters, of which the forward
primers were Mlu I-site-linked and the reverse primer Xho
I-site-linked. These PCR products were cloned into the
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reporter plasmids. CD166 30-UTR, and ﬂanking sequences
around pre-miRNA-9-1, which containing miR-9 putative
target sites were ampliﬁed and then inserted into the Xho
I/Not I sites of the psiCHECK2 vector (promega) as
previously reported (20). For overexpression studies, the
complete ORF sequences of P65, P50, P52, c-Rel and Rel
B were cloned into pcDNA3.1(+) expression vector
(Invitrogen). Veriﬁcation of these vectors is seen in
Supplementary Figure S1. Deletion constructs were
generated by a site-directed mutagenesis kit (Takara).
All the vectors have been veriﬁed via sequencing by
Invitrogen Inc (Shanghai, China).
Luciferase assay
Promoter and miRNA sensor reporter assays were per-
formed as described previously (20). Luciferase activity
was measured as chemiluminescence in a luminometer
(PerkinElmer Life Sciences, Boston, MA, USA) using
the Dual-Luciferase reporter assay system (Promega)
according to the manufacturer’s protocol.
Electrophoretic mobility shift assays
Electrophoretic mobility shift assays (EMSAs) were
performed using the light shift kit (Pierce, Rockford, IL,
USA). Five micrograms of nuclear extract proteins
[prepared by a kit from Active Motif and quantized by
BCA protein quantiﬁcation kit (Pierce)] were incubated
in 20ml of reaction mixture with or without excess of
DNA competitors on ice for 10min followed by the
addition of the biotin labeled probes (synthesized and 50
labeled by Sangon Inc, Shanghai, China). For super-shift
assays, 5mg antibodies were added to the reaction mixture
10min before the addition of the probe. All DNA–protein
complexes were resolved by electrophoresis on 5% native
polyacrylamide and trans-membrane to Immobilon-Ny+
(Millipore, Billerica, MA, USA).
Western-blot analysis
To determine protein expression levels, we prepared
total-cell extracts (by RIPA buffer, Beyotime Inc,
Haimen, China) and fractions from either cytoplasm or
nucleus (extracted by a kit from Active Motif sequen-
tially). The analysis was carried out by ECL western
blotting (Promega) according to the manufacturer’s
recommendations.
Cell migration assay
To carry out the wound healing assay, the cells were
plated onto 24-well plate. The monolayer HepG2 cells
were then scratched manually with a plastic pipette tip,
and after being washed with PBS, the wounded mono-
layers of the cells were transfected with either siRNA or
pcDNA 3.1 vector in serum free opti-MEM (Gibco) for
5h. Afterwards, transfection medium was replaced,
and cells were allowed to heal for 24–30h in DMEM
containing 10% FBS. To perform a rescue experiment,
1mg pcDNA3.1 or 50nM siRNA targeting CD166 was
co-transfected with 70nM either miR-9 mimics or miR-9
inhibitor into HepG2 cells.
To measure the cell migration activity, trans-well assays
were done using Corning 8.0-mm Transwell

cell culture
inserts (Corning, NY, USA). Membranes were coated
with puriﬁed ﬁbronectin (Sigma) at a concentration of
10mgm l
 1. After transfection, either siRNA or expression
vectors in opti-MEM medium for 5h, cells were collected
and resuspended in serum-free DMEM medium contain-
ing 0.1% bovine serum albumin. Subsequently, cells
(4 10
5ml
 1) were seeded in trans-well chambers.
After 24h incubation, the cells on the upper surface of
the ﬁlter were completely wiped away with a cotton
swab. The cells on the lower surfaces of the membrane
were ﬁxed with 100% methanol, stained with Giemsa
solution and counted under a microscope.
Statistical analysis
All data were expressed as the mean±SD. The statistical
signiﬁcance of differences between values was evaluated
by the Student’s t-test.
RESULTS
CD166 is upregulated after SD
CD166 mRNA expression levels were upregulated follow-
ing SD in both HepG2 and GQY-7701 cells; however,
CD166 mRNA levels decreased after 48h (compared to
that of 24h) in Bel-7402 cells (Figure 1A). The expression
pattern of CD166 protein was similar with that of mRNA,
but declined remarkably 48h after induction in all three
cell lines (Figure 1B). We then discovered that CD166
expression is negatively associated with serum concentra-
tion (Figure 1C). CHX, a protein synthesis inhibitor
(23,24), was applied to determine whether SD-induced
upregulation of CD166 is dependent upon translation.
Unlike in GQY-7701 and Bel-7402 cells, pre-treatment
with CHX in HepG2 cells signiﬁcantly inhibits the
starvation-induced effects as analyzed by real-time PCR
(Figure 1D).
A iB motif acts as an enhancer to CD166 gene
The transcription start site (TSS) of the human CD166
gene was identiﬁed by 50 RACE analysis and predicted
to be  235-bp upstream from our gene-speciﬁc nested
primer (Figure 2A). Sequencing of PCR products indi-
cated that the ﬁrst base was cytosine (C) (Figure 2B),
which is 35-bp downstream of the ﬁrst base provided by
National Center for Biotechnology Information (NCBI
Gene ID: 214).
To examine the transcriptional activity of the sequences
at the 50-end of the CD166 gene, various fragments of the
proximal sequence were cloned upstream of the ﬁreﬂy
luciferase reporter gene. A 50 deletion series with a ﬁxed
30-end at the +170 position (relative to the TSS) were
generated through PCR ampliﬁcation. All the constructs
(containing  880/ 768 fragment) tested were capable of
inducing a more signiﬁcant increase in luciferase activity
compared to those which lacked this region (Figure 2C).
6442 Nucleic Acids Research, 2011,Vol.39, No. 15This suggests that the most important 113 nucleotides of
the CD166 gene contain the enhancer element capable
of inducing CD166 expression.
We then performed a prediction using the software
MatInspector and TFSEARCH, which revealed a kB
motif (from  851 to  841) within this region
(Figure 2D). To conﬁrm the role of this 113-bp fragment
in transcriptional activity, miniﬁed sequences between
 880 and  465 were cloned into pGL3/Basic vector,
yielding the CD166 NF-kB reporter. Results indicated
this isolated fragment had promoter activity; however,
no signiﬁcant changes in luciferase activity were detected
before or after SD (Figure 2E).
To further test the role of this kB motif, we generated
a series of deletions within the CD166 NF-kB reporter
construct. The individual deletions in D1, D11 and D16
(which disrupts the kB motif) all reduced promoter
activity signiﬁcantly, whereas no disruption in promoter
activity was observed in the other constructs (Figure 2F).
This demonstrates that this kB motif may act as an
enhancer necessary for increasing transcriptional activity.
Recruitment of P50/P65 to the CD166 promoter
To analyze the locations and boundaries of chromatin
changes around kB motif after SD, we designed ﬁve
Figure 1. SD induces upregulation of CD166. (A) Change in CD166 mRNA level under SD during the whole detection period as indicated was
quantiﬁed by real-time PCR. *P<0.05 and **P<0.01 versus ‘0 min’ point. (B) Alteration of CD166 protein level by SD was detected by
western-blotting assays. (C) CD166 mRNA expression levels were measured at different serum (FBS) concentration as indicated. *P<0.05 and
**P<0.01 versus ‘10%’ point. (D) Cells were stimulated with BAY 11-7082 (100mM) or CHX (10mM) in combination with SD for 24h, then total
RNA was extracted for CD166 detection. N.S., non-signiﬁcant; *P<0.05 and **P<0.01 level using t-test. b-actin was treated as internal control
both for real-time PCR and western blotting.
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 465 for Chart-PCR assays (Figure 3A). Nuclei isolated
from HepG2 cells before and after SD were subjected to
limited digestion with a panel of restriction enzymes and
DNase I. When the nuclei were incubated with Mae III
and Sma I, starvation-dependent restriction enzyme
cleavages were apparent. In contrast, such cleavages
were not observed for other restriction enzyme sites,
including Dde I, Alu I, Sal I and Taq I (Figure 3B).
In addition, stronger cleavages by DNase I were only
detected when using primers a and b (Figure 3C), suggest-
ing the region from c to e does not cover the starvation-
response element. Because digestion with enzymes with
cut sites just upstream (Alu I/-1067) and downstream
(Sal I/-764) of the regions remain unchanged, we
mapped the boundaries undergoing chromatin alteration
Figure 2. Analysis of CD166 promoter activity. (A)5 0RACE was performed using the reverse 50RACE nested primer. (B) Mapping the TSS of
CD166 gene in hepatoma cells. (C) HepG2 cells were transiently co-transfected with reporter plasmids containing truncated versions of the promoter
region of the CD166 gene, as indicated, and pRL-TK. **P<0.01 level using t-test. (D) The kB motif presents in the promoter region predicated by
web software TFSEARCH and MatInspector, as indicated by a rectangle box. (E) CD166 NF-kB reporter is deﬁned as the promoter reporter
containing the miniﬁed upstream region (from  880 to  465), which the kB motif located in, and whose promoter activities were measured before
and after SD. (F) Scanning deletion analysis of the CD166 NF-kB reporter. As shown on the upper panel, a series of deletions were made within the
fragment from  880 to  465 of the NF-kB reporter. D1, D11 and D16 overlap the possible kB motif are indicted by gray circle in the lower panel.
Fireﬂy luciferase activity was normalized to renilla-luciferase activity, and the relative luciferase activities are presented as fold increase over the
promoter-less pGL3 basic vector.
6444 Nucleic Acids Research, 2011,Vol.39, No. 15following serum starvation to between  1067 and
 764bp, in which the kB motif is located.
To test DNA–protein interactions, we performed
EMSA using the DNA sequence from  858 to  834
bearing the kB motif and nuclear extracts from cells
1 day after SD. As illustrated, one strong DNA–protein
complex was detected when wild type probes (Figure 3D,
lanes 1, 12, 17 and 22) were used. Then, a series of fold
excess (10,20,30,40,50) unlabeled NF-kB consensus
sequence (lanes 2–6) was used to compete with the
complexes. We observed that the 40-fold excess of com-
petitor (lane 5) is enough to compete away the complexes,
possibly by sequestering the available transcription
factors present in the nuclear extract. In contrast,
the 50-fold excess of unlabeled mutated consensus
oligonucleotide bearing the disrupted kB could not
compete for protein binding capacity (lane 7). To verify
if NF-kB is involved in the formation of these protein–
DNA complexes, antibodies speciﬁc against P50 and
P65 were used. As shown [lanes 9 and 10 (HepG2),
14 and 15 (QGY-7701), 19 and 20 (Bel-7402)], although
no super-shifted bands were detected, the complexes
were greatly abrogated by either anti-P50 or anti-P65,
similar to previously reports (25–27); however,
non-speciﬁc control IgG (lanes 8, 13 and 18) had no
competed effects. We also detected that the amount of
DNA–protein complex began to increase around
30min following SD and remained high afterwards
(Figure 3E), suggesting the induction of the NF-kB
binding capacity.
Figure 3. Binding of NF-kB to the CD166 promoter. (A) Schematic representation of the restriction enzyme positions and primers used to map the
serum starvation-response site from  1190 to  465 (relative to the TSS) region by chart-PCR assays. (B) Nuclei of HepG2 cells before or after SD
for 1 day were puriﬁed and digested with 5–15U of different restriction enzymes, as indicated, per 100ml reaction system for 30min. Puriﬁed DNA
treated with or without enzymes (uncut) was semi-quantitated using primer sets a–F and R after 30 cycles of PCR reactions. (C) Puriﬁed DNA from
HepG2 cells before or after SD for 1 day treated with (cut) or without (uncut) 3U of DNase I for 5min at 37 C was semi-quantitated using primer
sets R and a–e, which were the same as indicated in Figure 3A after 29 PCR cycles. (D) Nuclear extracts from three different hepatoma cell lines
treated with SD for 1 day were assayed by EMSA using biotin-labeled oligonucleotide probes (from  858 to  834) and NF-kB consensus probes.
Shifted bands were veriﬁed by addition 5mg either nonspeciﬁc control IgG or speciﬁc antibodies against P65 or P50, as indicated. (E) EMSA assays
were performed using nuclear extracts from cells by treatment of SD for indicated time and wild-type probes (from  858 to  834). (F) ChIP analysis
was performed to qualitatively conﬁrm the interaction of NF-kB components, Pol II and Brg I with the promoter in vivo. As the negative controls,
the protein–DNA complexes were incubated without antibodies or with non-speciﬁc control IgG. The input DNA represents 1/20th of the starting
material. (G) In vivo interactions of NF-kB with CD166 promoter after SD upon suppression of P50/P65 protein by speciﬁc siRNA were determined
by ChIP assay.
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NF-kB components (P50, P65, P52 and c-Rel), RNA
polymerase II (Pol II) and key factor of SWI/SNF
complexes, Brg I interact with promoter in vivo before
and after SD. After 1 day of serum starvation, anti-P65
and anti-P50 antibodies speciﬁcally enriched the region,
which contains the kB motif. However, no inducible
enrichment was detected for other factors (Figure 3F).
We also detected P50/P65-speciﬁc siRNA could reduce
P50/P65 loading onto the promoter, compared to
non-speciﬁc control siRNA (N.C) (Figure 3G). The
above results suggest recruitment of P50/P65 to the
CD166 promoter after SD.
Contribution of P50/P65 to upregulation of CD166
Next, we determined whether deregulation of NF-kB
components affect promoter activity. In HepG2 cells,
promoter activities from the NF-kB reporter increased
only after transfection of P50/P65 expression vectors.
However, no signiﬁcant changes were detected after
overexpression P52, c-Rel or Rel B (Figure 4A, left
panel). Additionally, promoter activities from the same
vector could be reduced after using siRNA against
P50/P65 (Figure 4A, right panel).
BAY 11–7082, a known pharmacological inhibitor of
IkBa phosphorylation, was used to further deﬁne the
critical role of NF-kB on CD166 expression. As indicated
in Figure 1D, BAY 11–7082 can block the starvation-
induced upregulation of CD166 mRNA in all three cell
lines. To rule-out the possible off target effects of this
inhibitor, we monitored phosphorylation and degradation
of IkBa by western blotting. As expected, SD efﬁciently
promotes phosphorylation of IkBa. Subsequent degrad-
ation of the IkBa protein was most obvious in HepG2
cells. On the contrary, BAY 11-7082 could reduce
SD-induced effects on IkBa (Figure 4B).
Then we tested the effect of P50/P65 and SWI/SNF
complexes on endogenous CD166 expression.
Starvation-induced upregulation of CD166 was attenu-
ated to basal level after knockdown of P50/P65;
however, CD166 levels were not affected by knockdown
of either Brg I or BRM, two key factors of SWI/SNF
complexes. The enhanced effects of overexpression of
P50/P65 on CD166 mRNA expression were also
observed, which further conﬁrms the importance of
P50/P65 on transactivaion of CD166 gene (Figure 4C).
Similarly, the P50/P65 effect on CD166 expression was
also seen at protein level (Figure 4D). Interestingly,
when evaluating the LPS or TNFa-induced effects on
CD166 expression, no major changes were observed
when cells were cultured with FBS, yet both two
inducers could quantitatively enhance SD-promoted
effects (Figure 4E), suggesting activation of NF-kBb y
these inducers alone is not sufﬁcient to activate CD166
expression, but may synergize the impact of SD.
As chromatin structure represents the ultimate integra-
tion site of both environmental and differential inputs
which determine gene expression, we wanted to explore
whether P50/P65 directly affects chromatin accessibility
after SD. Chart-PCR was performed using restriction
enzymes (Mae III and Sma I) and DNase I. As
expected, the bands ampliﬁed from intact DNA isolated
from P50/P65 siRNA-treated cells after digestion with
restriction enzymes were more pronounced than those
transfected with non-speciﬁc control siRNA (Figure 4F).
Overall, P50/P65 upregulates CD166 expression may due
to enhancing open chromatin accessibility around the
kB motif independent of SWI/SNF complexes.
Activation and translocation of P50/P65 induced by SD
To verify whether expression of P50 or P65 has effects
on CD166 expression under SD, both real-time PCR
and western blotting assays were used. In HepG2 cells,
the P65 mRNA began to increase 24h after SD
(Supplementary Figure S2A), decreased rapidly after
re-addition of serum in 30min, and remained at low
level throughout the detection period (Supplementary
Figure S2D). For protein, total P65 induced grad-
ually after induction (Supplementary Figure S2B),
whereas reduced slowly after re-addition of serum
(Supplementary Figure S2D). With difference to HepG2
cells, no obvious change of P65 protein level was detected
after SD in other two cell lines, albeit P65 mRNA
decreased at 48h compared to that of 24h in QGY-7701
cells (Supplementary Figure S2A and B). We also detected
that P50 (both for mRNA and total protein) remained
almost unchanged in all three cell lines (Supplementary
Figure S2C). In addition, no alteration of P50 (both
for mRNA and total protein) was detected after
re-addition of serum in HepG2 cells (Supplementary
Figure S2D).
To further analyze the response of NF-kB to SD, P50/
P65 translocation was evaluated. SD-stimulated P50/P65
translocation to the nucleus, whereas cytoplasmic P50/P65
levels were reduced after SD in all three cell lines
(Supplementary Figure S2B and C), which is consistent
with nuclear translocation of a ﬁnite cytosolic pool of
these proteins. Speciﬁcally, it was also found that SD
resulted in accumulation of cytoplasmic P65 during the
early phase of stimulation (at least for the ﬁrst 3h) in
HepG2 cells, and eventually led to translocation of all
these induced P65 into the nucleus (Supplementary
Figure S2B). We next examined the effect of serum
re-addition on the amount of P50/P65 in HepG2 cells.
As shown in Supplementary Figure S2D, serum
re-addition decreased the amount of nuclear P50/P65,
whereas increased that of cytoplasmic (albeit both cyto-
plasmic and total P65 ﬁnally returned to the basal level),
suggesting the nuclear export of these proteins after
removal of the stimulation.
Suppression CD166 protein by miR-9
Unlike mRNA (Figure 1A), CD166 protein was markedly
reduced 48h after SD compared to that of 24h in all three
cell lines (Figure 1B). To investigate these results, we
explored whether protein synthesis of CD166 was
affected 24h after stimulation. As shown in Figure 5A,
the 30-UTR of CD166 contains two adjacent elements
complementary to miR-9 seed regions predicted by
Targetscan online software. To verify, miR-9 can
6446 Nucleic Acids Research, 2011,Vol.39, No. 15genuinely affect CD166 expression, sensors were con-
structed (described in the ‘Materials and Methods’
section). As indicated in Figure 5B, luciferase assays
revealed that overexpression of miR-9 could reduce the
renilla-luciferase activities from the wild sensor (lanes 3
versus 1). To inhibit the function of miR-9, 20-O-methyle
antisense inhibitory oligoribonucleotides targeted toward
miR-9 (50–70nM, lanes 4 and 5) were co-transfected, and
Figure 4. NF-kB contributes to upregulation of CD166. (A) Promoter activities from CD166 NF-kB reporter in HepG2 cells were measured after
overexpression of NF-kB components, as indicated, with FBS condition, *P<0.05 and **P<0.01 versus ‘Empty’ or knockdown either P65 or P50
using speciﬁc siRNA under SD, *P<0.05, versus ‘NC’. (B) Effects of SD with or without BAY 11–7082 (100mM) treatment on the amount and
phosphorylation of IkBa protein. b-actin was treated as internal control. (C) Total RNA from cells was extracted after 12h treatment with either
siRNA or pcDNA3.1, as indicated. Then CD166 mRNA levels were measured using real-time PCR. **P<0.01 level using t-test. (D) CD166 protein
levels from cells under similar treatment as described in (C) were assayed by western blotting. (E) Effects of LPS or TNFa on CD166 expression
before or after SD. (F) Open chromatin accessibility status of HepG2 cells under different treatment as indicated was measured via chart-PCR
(29 reaction cycles) using either DNase I, Mae III or Sma I by same primer sets used in Figure 3F.
Nucleic Acids Research, 2011,Vol.39, No. 15 6447Figure 5. Upregulation of miR-9 leads to down-regulation of CD166. (A) CD166 30-UTR contains two miR-9 target sites predicted by Targetscan
online software. (B) psiCHECK2 vectors containing CD166 30-UTR with (wild) or without (Del-9) predicted miR-9-binding sites were co-transfected
with miR-9 (50–70nM) or miR-9 inhibitor (50–70nM). Luciferase assays were performed 1 day post-transfection. *P<0.05 versus ‘Wild+NC’, and
#P<0.05 versus ‘Wild+miR-9 (higher dose)’. (C) SD-treated cells were transfected with or without miR-9 (50–70nM) or anti-miR-9 (70nM). CD166
was then detected by western blotting 1 day post-transfection. (D) Total RNA from hepatoma cells were detected for miR-9 after SD at different
time point as indicated by real-time PCR. **P<0.01 versus ‘0 min’ point. (E) Activities of miR-9 before and after SD were measured via
dual-luciferase assays. (F) Primary miRNAs (pri-miR-9-1 and pri-miR-9-2) expression levels were measured before and after SD by real-time
PCR. (G) Expression levels of mature miR-9 and its precursor pri-miR-9-1 were detected with incubation of DMSO or BAY 11-7082 under SD
at different time points as indicated in HepG2 cells. Renilla-luciferase activities were normalized to Fireﬂy luciferase activities (B and E).
6448 Nucleic Acids Research, 2011,Vol.39, No. 15it was observed that relative-luciferase activities were
upregulated compared to that of control (lane 5
versus 1). To further conﬁrm these putative target sites
of miR-9, a deletion assay was performed. Luciferase
assays indicated that overexpression of miR-9 had no
effect on deleted 30-UTR compared to the wild type
(lane 6 versus 3). Instead, the increased luciferase
activity that was observed may have resulted from a
failure of endogenous miR-9’s effect to the sensor (lane
6 versus 1). It was also conﬁrmed that CD166 protein
levels could be suppressed by miR-9. Transfection with
anti-miR-9 blocked miR-9 function, thus resulting in
enhanced CD166 protein level (Figure 5C).
Next we evaluated both expression and activity of
miR-9 before and after SD. Results indicated that miR-9
began to upregulate 24h following SD (Figure 5D).
To verify induction of miR-9 activity, sensors were
constructed as described previously (20). Reduction of
renilla-luciferase activity suggests induction of miRNAs
activity. As expected, the activities from miR-9 sensors
decreased signiﬁcantly after SD (Figure 5E). Mature
miR-9 can be generated from its precursor pri-miR-9-1
and -2 in human genome, therefore it is important to
clarify which precursor is associated with upregulation
of miR-9. As shown in Figure 5F, only pri-miR-9-1
increased signiﬁcantly after SD while pri-miR-9-2
decreased. We also conﬁrmed that induction of both
mature miR-9 and pri-miR-9-1 by starvation could be
blocked by NF-kB inhibitor, BAY 11-7082 (Figure 5G).
Taken together, starvation induced up-regulation of
miR-9 may be associated with induction of pri-miR-9-1
via NF-kB. Additionally, miR-9 may have a negative role
in controlling CD166 protein level.
Activation of pri-miR-9-1 promoter via P50/P65
To conﬁrm whether sequences upstream of pre-miR-9-1
had promoter capacity, fragments encompassing from
 914 to  425 (relative to the ﬁrst base of pre-miR-9-1)
with or without the putative kB motif (from  693 to
 681) were cloned into the pGL3/Basic vector. As
shown in Figure 6A, after SD, the promoter activity can
be signiﬁcantly induced by 1.73-fold compared to the
basal level. Also, deletion of the kB motif resulted in
almost total loss of its promoter activity.
EMSA was then performed to identify the DNA
sequence from  700 to  673, which overlaps kB motif,
has protein-binding capacity. The probes which interacted
with nuclear extracts from hepatoma cells 1 day after SD
lead to generation of a single band (Figure 6B, lanes 1, 6
and 11), which could be competed by NF-kB consensus
probe (lanes 2, 7 and 12). Super-shift assays using
antibodies speciﬁc against either P50 or P65 resulted in
disruption of the band, whereas non-speciﬁc control IgG
had no signiﬁcant effects (similar with results illustrated
in Figure 3D). Then we investigated the inﬂuence of
starvation on DNA–protein complex formation at this
promoter region. After treatment, the amount of DNA–
protein complex increased progressively (began at 3h)
in a time-dependent manner (Figure 6C).
To conﬁrm P50/P65 has genuine effects on miR-9-1, we
used gain–loss of function experiments. Overexpression of
either P50 or P65 could enhance both expression and
promoter activities of miR-9, but in contrast, knockdown
by siRNA had the opposite effects (Figure 6D and E).
As miR-9 is previously reported to be upregulated by
both LPS and TNFa in human polymorphonuclear
neutrophils (PMN) and monocytes (46), we analyzed
whether these two stimuli exert analogous function on
miR-9 in hepatoma cells. As shown in Figure 6F, both
LPS and TNF could induce miR-9 expression in all
three cell lines, suggesting the regulatory mechanism
may be similar. Additionally, siRNA against P50/P65
reduced open chromatin accessibility induced by SD,
around the kB motif of pri-miR-9-1 promoter, as indicated
in Figure 6G. Furthermore, we observed that P50/P65 is
recruited to kB motif of pri-miR-9-1 promoter 24h after
SD by ChIP assays (Figure 6H, left panel). It is also con-
ﬁrmed that P50/P65-speciﬁc siRNA decreased P50/P65
loading onto the promoter, compared to non-speciﬁc
control siRNA (Figure 6H, right panel). In summary,
NF-kB P50/P65 plays a similar role in activation of both
CD166 and pri-miR-9-1 promoters.
The miR-9 promotes cell migration via inhibitory to
CD166
As shown in Figure 7A, the CD166 protein in HepG2 cells
transfected with miR-9 mimics (70nM) was gradually
downregulated under SD while miR-9 inhibitor (70nM)
has the opposite effects. As Masedunskasa et al. (28)
reported that CD166 markedly inhibited migration of
THP1 and HL60 monocytes. Then we explored whether
similar effects of the CD166 interaction with miR-9 in
controlling cell migration also exist in hepatoma cells. It
was observed that overexpression of miR-9 signiﬁcantly
stimulated cell migration, while anti-miR-9 suppressed
such effect. Furthermore, knockdown of CD166 by
RNA interference promotes migration, which resembles
that of miR-9, whereas overexpression of CD166 has the
opposite effects (Figure 7B).
To further conﬁrm the above results (Figure 7B), the
trans-well approach was used. Consistently, the results
indicated that cell migration can be enhanced by either
overexpression of miR-9 or knockdown of CD166,
while migration can be suppressed by either inhibition of
miR-9 or overexpression of CD166 (Figure 7C). To rule
out the possibility that miR-9-promoted cell migration
through inhibition of other genes, rescue experiments
were performed. The results showed that overexpression
of CD166 reduced the effects induced by miR-9
(Figure 7D, lane 3 versus 2), whereas knockdown of
CD166 rescued inhibitory effects by anti-miR-9 (lane 5
versus 4). All the results suggest that miR-9 promoted
cell migration is largely via inhibition of its genuine
target, CD166 in hepatoma cells.
DISCUSSION
In our study, we illuminated the mechanism by which SD
mediates differential regulation of CD166 expression on
Nucleic Acids Research, 2011,Vol.39, No. 15 6449Figure 6. P50/P65 mediates up-regulation of miR-9 via interaction with pri-miR-9-1 promoter. (A) Promoter activities of fragment from  914 to
 425 relative to pre-miR-9-1 with or without putative kB motif were detected before and after SD in HepG2 cells. **P<0.01. (B) Nuclear extracts
from cells 1 day after SD were assayed by EMSA using biotin-labeled oligonucleotide probes (from  700 to  673) and NF-kB consensus probes.
Shifted bands were veriﬁed by addition of 5mg either non-speciﬁc control IgG or speciﬁc antibodies against P65 or P50, as indicated. (C) EMSA
assays were performed using nuclear extracts from three hepatoma cell lines after SD for indicated time and wild-type probes (from  700 to  673).
(D) Promoter activities from miR-9-1 reporter were measured after overexpression of NF-kB components, as indicated, with FBS condition or
knockdown either P65 or P50 using speciﬁc siRNA under SD. *P<0.05, and **P<0.01 versus the control (NC or empty). (E) Total RNA from cells
was extracted after treatment with siRNA or pcDNA3.1 vector targeting either P50 or P65. Then miR-9 levels were measured using real-time PCR.
*P<0.05, versus the control and
#P<0.05 versus the SD. (F) Effects of LPS or TNFa on miR-9 expression. *P<0.05, and **P<0.01 versus the
control. (G) Open-chromatin-accessibility status around the kB motif under different treatment as indicated in HepG2 cells was measured via
Chart-PCR (31 reaction cycles) using DNase I by same primer sets used in Figure 6H. (H) ChIP analysis was performed to qualitatively conﬁrm
the interaction of NF-kB components, P50 and P65 with the miR-9-1 promoter in vivo (left panel). Right panel, in vivo interactions of NF-kB with
pri-miR-9-1 promoter after SD upon suppression of P50/P65 protein by speciﬁc siRNA were determined by ChIP assay again.
6450 Nucleic Acids Research, 2011,Vol.39, No. 15Figure 7. miR-9 promotes cell migration via inhibition to CD166. (A) Changes of CD166 protein in HepG2 cells were detected by western-blotting
assays after transfection with 70nM either miR-9 mimics or miR-9 inhibitor under SD at different time point as indicated (left panel). The relative
CD166 protein expression levels were quantitated, and the intensities of the bands of CD166 were normalized to those of b-actin (right panel).
*P<0.05, and **P<0.01 versus the ‘miR-9 treated-0 h’;
#P<0.05 and
##P<0.01 versus the ‘anti-miR-9 treated 0 h’. (B) Cells were wounded before
transfection with either siRNA or expression vectors as indicated. Then, the culture was continued for 24h. The bar, 200mm. (C) Cell-migration
assay was carried out with trans-well culture chambers. Transfected with either siRNA or pcDNA3.1 expression vectors as described in (B), 4 10
4
HepG2 cells were seeded into the upper wells. After 24h, the cells migrating to the lower surface of the membrane were examined (original
magniﬁcation 40 ). Five different areas of migrated cells were counted for each data point (n=5), and the counts were averaged (right panel).
The data is presented relative to cells transfected with negative control siRNA, which is normalized to 100%. The asterisk indicates a signiﬁcant
difference (*P<0.05). (D) CD166 reverse miR-9 promoted cell-migration activity. Either miR-9 mimics or inhibitor were co-transfected with CD166
expression vector or siRNA into HepG2 cells for 30h. Afterwards, average rates of wound closure were calculated from three independent
experiments. The bar, 200mm.
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P50/P65 into the nucleus occurs after phosphorylation of
IkBa (Figure 4B, Supplementary Figure S2B and C);
(ii) recruitment of P50/P65 to both CD166 and pri-miR-
9-1 promoters, which in turn enhances open chromatin
accessibility (Figures 3, 4 and 6); and (iii) suppression of
CD166 translation by miR-9 results in decreasing CD166
protein levels later after induction (Figures 1B, 5A–C
and 7A).
Biological systems in cells ultimately need to be
explained in terms of the activity, regulation and modi-
ﬁcation of proteins. The ubiquitous occurrence of
post-transcriptional regulation makes mRNA an imper-
fect proxy for such information (29), which is also
supported by our observation that induction of CD166
protein and mRNA is inconsistent (Figure 1A and B).
miRNAs are endogenous  22-nt non-coding RNAs,
whose action is to specify translational repression
without affecting the levels of the targeted mRNA
(30–32). By luciferase and western-blotting assays, we con-
ﬁrmed that miR-9 can genuinely affect CD166 expression
(Figure 5A–C and 7A). Inhibition of CD166 by miR-9 was
also veriﬁed when cell migration assays were utilized
(Figure 7B–D). Moreover, we detected that miR-9 was
not up-regulated until 24h after induction (Figure 5D),
which may explain why CD166 protein levels decreased
at 48h compared to that of 24h (Figure 1B).
Using BAY 11-7082, which decreases NF-kB activation
(33), we found both CD166 mRNA (Figure 1D) and
miR-9 (Figure 5G) were greatly inhibited. Also, both
endogenous expression levels and promoter activities
were associated with the amounts of P50 and P65
(Figure 4A, C and D and 6D and E). Furthermore, both
in vitro and in vivo experiments revealed P50/P65
hetero-dimer is recruited to the promoters of both
CD166 and miR-9-1 genes once serum is deprived
(Figures 3 and 6). Consistent with previous report that
miR-9 could be induced by LPS and TNFa (34), we also
veriﬁed the same effects by these two typical NF-kB
inducers in hepatoma cells (Figure 6F). In contrast, LPS
and TNFa only upregulated endogenous CD166 expres-
sion after serum withdrawal (Figure 4E). Further results,
in which CD166 expression was correlated with
NF-kB-binding activity at its promoter (Figure 1A and
3E), indicate that the concentration of activated NF-kB
must exceed a critical threshold before transcription of
CD166 initiates. We propose here that the amounts of
activated NF-kB induced by LPS or TNFa fail to reach
this threshold; however, synergistic effects occur by
additional activated NF-kB once transcription of
CD166 is fully initiated by SD. Additionally, some other
proteins may also aid NF-kB mediated transactivation of
endogenous CD166. In this study, we observed a great
decreasing activity in promoter without  880 to  768
(which contains a kB motif) both before and after SD
(Figure 2C). Although the sequence from  880 to  465
has an obvious promoter activity, no inducible effects
were detected after induction (Figure 2E). Such results
may due to the loss of the region from  143 to  124,
which is also responsive to SD (Figure 2C), albeit no
valuable information has been obtained from online
prediction software, we hypothesize this region may
interact with other proteins, which assists recruitment of
P50/P65 to the CD166 promoter.
Very recently, King et al. (35) reported another distinct
functional kB motif ( 643/ 634 relative to our TSS,
which is 156-bp upstream from the one identiﬁed by
King et al.) on the endogenous CD166 promoter, which
can be induced by overexpression of P65 in melanoma
cells lines. However, there seems to be no functional role
of this site in hepatoma cells, because the little impacts on
promoter activity after deletion the region compassing
from  649 to  607 (Figure 2C). Although the presence
of kB motif in pri-miR-9-1 promoter has been predicted by
bioinformatics previously (36), we conﬁrmed this possi-
bility experimentally for the ﬁrst time. Thereby, in the
present study, we have revealed another two novel
NF-kB target genes in hepatoma cells. NF-kBi s
involved in stimulating cell proliferation, inhibiting apop-
tosis, and promoting metastasis and angiogenesis (37).
More than 180 NF-kB target genes have been proposed
and many of them, such as BclII, cyclin D1, matrix
metalloproteinase-9 and vascular endothelial growth
factor, regulate critical steps of cancer progression (37).
Therefore, it is important to point out that CD166 and
miR-9 may not be the only downstream targets of NF-kB
that contribute to development of cancer. Further study
is needed to elucidate the genes and signaling pathways
that are critical mechanisms of NF-kB activity that
participate in liver cancer development and progression.
One unexpected ﬁnding was that unlike other two cell
lines, QGY-7701 and Bel-7402, upregulation of CD166
mRNA following serum starvation could be greatly
reduced after treatment of CHX in HepG2 cells
(Figure 1D), suggesting dependence of translation.
Here, we illustrate that both mRNA and protein levels
of P65 can be simultaneously induced in HepG2 cells
(Supplementary Figure S2A and B), inhibition of
translation, and impaired protein expression of P65,
which results in blocking CD166 gene activation. By com-
parison, no alteration of P65 was detected in QGY-7701
and Bel-7402 cells, which may explain why CHX had
no such effect (Figure 1D). Translocation the most
highly increased P65 concentration into the nucleus
(Supplementary Figure S2B) results in the strongest
upregulation of CD166 in HepG2 cells compared to
other two cell lines (Figure 1). The patterns of mRNA
and protein expression of P65 were not synchronized
because mRNA was not upregulated until induction for
24h, however, the protein began to increase just 2h after
SD. In addition, both P65 mRNA and protein decreased
after re-addition of FBS (Supplementary Figure S2D).
Thereby, we assume that upregulation of P65 protein
after SD may be due to two independent mechanisms;
the ﬁrst one may be transcriptional activation of P65
gene in a slow and moderate manner (however, this
activation is unstable and may easily lose its function
immediately after re-addition of serum accompanied by
6452 Nucleic Acids Research, 2011,Vol.39, No. 15the prompt degradation of excess mRNA) and the other is
at the post-transcriptional level. As previously reported,
NF-kB function is regulated by ubiquitin-mediated
proteolysis of its P65 subunit. Upon cytokine treatment,
Pin1 binds to the pThr254-Pro motif in P65, resulting in
protein stability of P65 and enhanced NF-kB activity (38),
and phosphorylation of P65 prevents its degradation.
Pim-1 may act as a further kinase responsible for the
phosphorylation of P65 (39). Such events may occur in
cells under SD, and miRNA may also play a potential
role in regulation of P65, yet further studies are required
to explore such mechanisms underlying the upregulation
of P65 in HepG2 cells.
Some other proteins that are critical for activity of the
endogenous CD166 promoter may not be necessary in the
transient assay because of the high-plasmid copy number
or the aberrant chromatin structure that assembles on
transiently transfected plasmids (34,40). By chromatin
accessibility assay, we observed the kB motif is in two
linker regions, with greater accessibility to restriction
enzymes (Mae III and Sma I) and DNase I after SD
compare to that at basal level (Figure 3A–C), which is
similar with studies described in other promoters
(20,23,41). Changes in the accessibility of nucleosome-
packaged DNA can be mediated by the SWI/SNF
remodeling complex (41–43), but we do not believe the
SWI/SNF complex works on the CD166 promoter after
SD, because Brg I, a key factor of SWI/SNF does not
recruit to sequences around the kB motif (Figure 3F).
Moreover, knockdown assays showed that neither
BRM nor Brg I has obvious negative effects on
starvation-induced upregulation of CD166 expression
(Figure 4C). Other mechanisms may involve chromatin
remodeling around the kB motif after induction, as
reported previously, sequential recruitment of P65, accom-
panying ordered elevation of the levels of histone H4 and
H3 acetylation at the native TGF-beta1 promoter after
IL-1beta stimulation (44). Furthermore, NF-kB increases
the recruitment of HAT p300 and acetylated histones H3
and H4 of the FasL promoter, thus making more open
chromatin accessibility and helping to expose the kB motif
(45). P50/P65 binding to the CD166 promoter results in
the activation of the promoter and a more open chromatin
status, which may be dependent on histone modiﬁcation,
but further studies should be done to clarify the
underlying mechanism.
In conclusion, in this work, we demonstrate that a novel
negative auto-regulatory loop in which P50/P65 mediates
differential regulation of CD166 via interaction with
miR-9 after SD in hepatoma cells (Figure 8). Induction
of CD166 and miR-9 provides a means to smooth out the
ﬂuctuations in gene expression and ﬁne tune the synthesis
of protein, thus allowing the speciﬁc response to correctly
proceed.
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